

Mallika Imwong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7591524/publications.pdf>

Version: 2024-02-01

124
papers

14,249
citations

41344

49
h-index

21540

114
g-index

136
all docs

136
docs citations

136
times ranked

8820
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular surveillance for operationally relevant genetic polymorphisms in <i>Plasmodium falciparum</i> in Southern Chad, 2016–2017. <i>Malaria Journal</i> , 2022, 21, 83.	2.3	5
2	Artemisinin resistance in the malaria parasite, <i>Plasmodium falciparum</i> , originates from its initial transcriptional response. <i>Communications Biology</i> , 2022, 5, 274.	4.4	33
3	Comparative analysis of targeted next-generation sequencing for <i>Plasmodium falciparum</i> drug resistance markers. <i>Scientific Reports</i> , 2022, 12, 5563.	3.3	3
4	Measurement of gene amplifications related to drug resistance in <i>Plasmodium falciparum</i> using droplet digital PCR. <i>Malaria Journal</i> , 2021, 20, 120.	2.3	4
5	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant <i>falciparum</i> malaria: a cluster-randomised trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1579-1589.	9.1	8
6	Study protocol: an open-label individually randomised controlled trial to assess the efficacy of artemether-lumefantrine prophylaxis for malaria among forest goers in Cambodia. <i>BMJ Open</i> , 2021, 11, e045900.	1.9	7
7	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with <i>Plasmodium vivax</i> Malaria. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0130221.	3.2	10
8	Clustering of malaria in households in the Greater Mekong Subregion: operational implications for reactive case detection. <i>Malaria Journal</i> , 2021, 20, 351.	2.3	7
9	Evolution of Multidrug Resistance in <i>Plasmodium falciparum</i> : a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0112121.	3.2	21
10	Assessment of <i>Plasmodium</i> antigens and CRP in dried blood spots with multiplex malaria array. <i>Journal of Parasitic Diseases</i> , 2021, 45, 479-489.	1.0	4
11	Genetic population of <i>Plasmodium knowlesi</i> during pre-malaria elimination in Thailand. <i>Malaria Journal</i> , 2021, 20, 454.	2.3	4
12	Combined effects of double mutations on catalytic activity and structural stability contribute to clinical manifestations of glucose-6-phosphate dehydrogenase deficiency. <i>Scientific Reports</i> , 2021, 11, 24307.	3.3	6
13	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of <i>Plasmodium vivax</i> infections: a randomized, controlled trial in Lao PDR. <i>Malaria Journal</i> , 2020, 19, 4.	2.3	4
14	Polymorphisms in <i>Plasmodium vivax</i> antifolate resistance markers in Afghanistan between 2007 and 2017. <i>Malaria Journal</i> , 2020, 19, 251.	2.3	3
15	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1470-1480.	9.1	94
16	Genetic analysis of the orthologous <i>crt</i> and <i>mdr1</i> genes in <i>Plasmodium malariae</i> from Thailand and Myanmar. <i>Malaria Journal</i> , 2020, 19, 315.	2.3	1
17	Functional and structural analysis of double and triple mutants reveals the contribution of protein instability to clinical manifestations of G6PD variants. <i>International Journal of Biological Macromolecules</i> , 2020, 158, 884-893.	7.5	7
18	Genome-wide microsatellite characteristics of five human <i>Plasmodium</i> species, focusing on <i>Plasmodium malariae</i> and <i>P. ovale curtisi</i> . <i>Parasite</i> , 2020, 27, 34.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Utility of Plasmodium falciparum DNA from rapid diagnostic test kits for molecular analysis and whole genome amplification. <i>Malaria Journal</i> , 2020, 19, 193.	2.3	8
20	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. <i>Lancet, The</i> , 2020, 395, 1345-1360.	13.7	182
21	Molecular characterization of Plasmodium falciparum antifolate resistance markers in Thailand between 2008 and 2016. <i>Malaria Journal</i> , 2020, 19, 107.	2.3	11
22	Polymorphic markers for identification of parasite population in Plasmodium malariae. <i>Malaria Journal</i> , 2020, 19, 48.	2.3	3
23	Mass drug administrations with dihydroartemisinin-piperazine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials. <i>PLoS ONE</i> , 2020, 15, e0228190.	2.5	6
24	Genetic dissociation of three antigenic genes in Plasmodium ovale curtisi and Plasmodium ovale wallikeri. <i>PLoS ONE</i> , 2019, 14, e0217795.	2.5	7
25	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 943-951.	9.1	219
26	Determinants of dihydroartemisinin-piperazine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. <i>Lancet Infectious Diseases, The</i> , 2019, 19, 952-961.	9.1	252
27	Polymorphisms in Pvkelch12 and gene amplification of Pvpfmspsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. <i>Malaria Journal</i> , 2019, 18, 114.	2.3	4
28	Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. <i>Journal of Infectious Diseases</i> , 2019, 220, 448-456.	4.0	17
29	The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. <i>PLoS Medicine</i> , 2019, 16, e1002745.	8.4	105
30	The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos. <i>Malaria Journal</i> , 2019, 18, 449.	2.3	7
31	Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. <i>Nature Communications</i> , 2019, 10, 5595.	12.8	70
32	Chloroquine Versus Dihydroartemisinin-Piperazine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. <i>Clinical Infectious Diseases</i> , 2019, 68, 1311-1319.	5.8	49
33	Simultaneous Quantification of Plasmodium Antigens and Host Factor C-Reactive Protein in Asymptomatic Individuals with Confirmed Malaria by Use of a Novel Multiplex Immunoassay. <i>Journal of Clinical Microbiology</i> , 2019, 57, .	3.9	31
34	Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi. <i>Journal of Infectious Diseases</i> , 2019, 219, 695-702.	4.0	117
35	Contribution of Asymptomatic Plasmodium Infections to the Transmission of Malaria in Kayin State, Myanmar. <i>Journal of Infectious Diseases</i> , 2019, 219, 1499-1509.	4.0	50
36	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. <i>Lancet, The</i> , 2018, 391, 1916-1926.	13.7	131

#	ARTICLE	IF	CITATIONS
37	A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant <i>Falciparum</i> Malaria in Cambodian Villages. <i>Clinical Infectious Diseases</i> , 2018, 67, 817-826.	5.8	48
38	The dynamic of asymptomatic <i>Plasmodium falciparum</i> infections following mass drug administrations with dihydroartemisinin+piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. <i>Malaria Journal</i> , 2018, 17, 405.	2.3	18
39	Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. <i>Malaria Journal</i> , 2018, 17, 427.	2.3	16
40	Effectiveness and safety of 3 and 5 day courses of artemether+lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in an area of emerging artemisinin resistance in Myanmar. <i>Malaria Journal</i> , 2018, 17, 258.	2.3	27
41	Genetic polymorphisms in the circumsporozoite protein of <i>Plasmodium malariae</i> show a geographical bias. <i>Malaria Journal</i> , 2018, 17, 269.	2.3	12
42	Genetic diversity of three surface protein genes in <i>Plasmodium malariae</i> from three Asian countries. <i>Malaria Journal</i> , 2018, 17, 24.	2.3	9
43	Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border. <i>Malaria Journal</i> , 2018, 17, 30.	2.3	16
44	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in <i>Plasmodium vivax</i> Malaria. <i>Clinical Infectious Diseases</i> , 2018, 67, 1543-1549.	5.8	52
45	Operational Performance of a <i>Plasmodium falciparum</i> Ultrasensitive Rapid Diagnostic Test for Detection of Asymptomatic Infections in Eastern Myanmar. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	3.9	49
46	The spread of artemisinin-resistant <i>Plasmodium falciparum</i> in the Greater Mekong subregion: a molecular epidemiology observational study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 491-497.	9.1	371
47	Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1022-1023.	9.1	136
48	A multi-level spatial analysis of clinical malaria and subclinical <i>Plasmodium</i> infections in Pailin Province, Cambodia. <i>Heliyon</i> , 2017, 3, e00447.	3.2	23
49	Submicroscopic <i>Plasmodium</i> prevalence in relation to malaria incidence in 20 villages in western Cambodia. <i>Malaria Journal</i> , 2017, 16, 56.	2.3	40
50	Molecular and immunological analyses of confirmed <i>Plasmodium vivax</i> relapse episodes. <i>Malaria Journal</i> , 2017, 16, 228.	2.3	8
51	<i>Plasmodium vivax</i> genetic diversity and heterozygosity in blood samples and resulting oocysts at the Thai-Myanmar border. <i>Malaria Journal</i> , 2017, 16, 355.	2.3	7
52	<i>Plasmodium falciparum</i> Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. <i>Malaria Journal</i> , 2017, 16, 480.	2.3	20
53	A trade off between catalytic activity and protein stability determines the clinical manifestations of glucose-6-phosphate dehydrogenase (G6PD) deficiency. <i>International Journal of Biological Macromolecules</i> , 2017, 104, 145-156.	7.5	35
54	Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant <i>falciparum</i> malaria: A pilot trial in four villages of Eastern Myanmar. <i>Wellcome Open Research</i> , 2017, 2, 81.	1.8	71

#	ARTICLE	IF	CITATIONS
55	Four human Plasmodium species quantification using droplet digital PCR. PLoS ONE, 2017, 12, e0175771.	2.5	49
56	Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1540-1550.	1.4	108
57	Chloroquineâ€“Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1782-1787.	1.4	13
58	Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia. Malaria Journal, 2016, 15, 484.	2.3	12
59	Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2016, 15, 296.	2.3	45
60	Analysis of anti-malarial resistance markers in pfmdr1 and pfcrt across Southeast Asia in the Tracking Resistance to Artemisinin Collaboration. Malaria Journal, 2016, 15, 541.	2.3	30
61	Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2016, 60, 4055-4062.	3.2	4
62	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	2.3	43
63	Declining Efficacy of Artemisinin Combination Therapy Against <i>P. falciparum</i> Malaria on the Thaiâ€“Myanmar Border (2003â€“2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	5.8	178
64	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
65	Use of Blood Smears and Dried Blood Spots for Polymerase Chain Reactionâ€“Based Detection and Quantification of Bacterial Infection and Plasmodium falciparum in Severely Ill Febrile African Children. American Journal of Tropical Medicine and Hygiene, 2016, 94, 322-326.	1.4	6
66	Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: Decreased stability and catalytic efficiency contribute to the clinical phenotype. Molecular Genetics and Metabolism, 2016, 118, 84-91.	1.1	30
67	Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malaria Journal, 2016, 15, 181.	2.3	54
68	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. Malaria Journal, 2016, 15, 240.	2.3	21
69	K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar. Malaria Journal, 2016, 15, 110.	2.3	27
70	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malaria Journal, 2016, 15, 121.	2.3	8
71	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. Journal of Infectious Diseases, 2016, 213, 1322-1329.	4.0	108
72	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147

#	ARTICLE	IF	CITATIONS
73	Dihydrofolate-Reductase Mutations in <i>Plasmodium knowlesi</i> Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. <i>PLoS ONE</i> , 2016, 11, e0149519.	2.5	17
74	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. <i>PLoS ONE</i> , 2016, 11, e0158656.	2.5	13
75	Prevalence of <i>Plasmodium falciparum</i> Molecular Markers of Antimalarial Drug Resistance in a Residual Malaria Focus Area in Sabah, Malaysia. <i>PLoS ONE</i> , 2016, 11, e0165515.	2.5	9
76	An outbreak of artemisinin resistant <i>falciparum</i> malaria in Eastern Thailand. <i>Scientific Reports</i> , 2015, 5, 17412.	3.3	50
77	Elimination of <i>Plasmodium falciparum</i> in an area of multi-drug resistance. <i>Malaria Journal</i> , 2015, 14, 319.	2.3	39
78	The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. <i>Malaria Journal</i> , 2015, 14, 381.	2.3	163
79	Efficient in vitro refolding and functional characterization of recombinant human liver carboxylesterase (CES1) expressed in <i>E. coli</i> . <i>Protein Expression and Purification</i> , 2015, 107, 68-75.	1.3	13
80	Genetic architecture of artemisinin-resistant <i>Plasmodium falciparum</i> . <i>Nature Genetics</i> , 2015, 47, 226-234.	21.4	515
81	Spread of artemisinin-resistant <i>Plasmodium falciparum</i> in Myanmar: a cross-sectional survey of the K13 molecular marker. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 415-421.	9.1	363
82	Artemisinin resistance in Myanmar – Authors' reply. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1002-1003.	9.1	0
83	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. <i>Science</i> , 2015, 347, 431-435.	12.6	362
84	Independent Emergence of Artemisinin Resistance Mutations Among <i>Plasmodium falciparum</i> in Southeast Asia. <i>Journal of Infectious Diseases</i> , 2015, 211, 670-679.	4.0	368
85	A Population Survey of the Glucose-6-Phosphate Dehydrogenase (G6PD) 563C>T (Mediterranean) Mutation in Afghanistan. <i>PLoS ONE</i> , 2014, 9, e88605.	2.5	13
86	High-Throughput Ultrasensitive Molecular Techniques for Quantifying Low-Density Malaria Parasitemias. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3303-3309.	3.9	181
87	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2014, 371, 411-423.	27.0	1,753
88	Genetic Variability of <i>Plasmodium malariae</i> dihydropteroate synthase (dhps) in Four Asian Countries. <i>PLoS ONE</i> , 2014, 9, e93942.	2.5	6
89	Prevalence of antifolate resistance mutations in <i>Plasmodium falciparum</i> isolates in Afghanistan. <i>Malaria Journal</i> , 2013, 12, 96.	2.3	12
90	Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. <i>Malaria Journal</i> , 2013, 12, 289.	2.3	51

#	ARTICLE	IF	CITATIONS
91	Multiple populations of artemisinin-resistant <i>Plasmodium falciparum</i> in Cambodia. <i>Nature Genetics</i> , 2013, 45, 648-655.	21.4	424
92	Reduced Susceptibility of <i>Plasmodium falciparum</i> to Artesunate in Southern Myanmar. <i>PLoS ONE</i> , 2013, 8, e57689.	2.5	177
93	The First <i>Plasmodium vivax</i> Relapses of Life Are Usually Genetically Homologous. <i>Journal of Infectious Diseases</i> , 2012, 205, 680-683.	4.0	78
94	A Major Genome Region Underlying Artemisinin Resistance in Malaria. <i>Science</i> , 2012, 336, 79-82.	12.6	334
95	Long-term storage limits PCR-based analyses of malaria parasites in archival dried blood spots. <i>Malaria Journal</i> , 2012, 11, 339.	2.3	39
96	Analysis of <i>Plasmodium falciparum</i> diversity in natural infections by deep sequencing. <i>Nature</i> , 2012, 487, 375-379.	27.8	450
97	Genotyping of <i>Plasmodium vivax</i> Reveals Both Short and Long Latency Relapse Patterns in Kolkata. <i>PLoS ONE</i> , 2012, 7, e39645.	2.5	41
98	High genetic polymorphism of relapsing <i>P. vivax</i> isolates in northwest Colombia. <i>Acta Tropica</i> , 2011, 119, 23-29.	2.0	31
99	Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. <i>Malaria Journal</i> , 2011, 10, 113.	2.3	53
100	Population Genetic Analysis of <i>Plasmodium falciparum</i> Parasites Using a Customized Illumina GoldenGate Genotyping Assay. <i>PLoS ONE</i> , 2011, 6, e20251.	2.5	63
101	Exploring the Contribution of Candidate Genes to Artemisinin Resistance in <i>Plasmodium falciparum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2886-2892.	3.2	110
102	Two Nonrecombining Sympatric Forms of the Human Malaria Parasite <i>Plasmodium ovale</i> Occur Globally. <i>Journal of Infectious Diseases</i> , 2010, 201, 1544-1550.	4.0	310
103	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated <i>falciparum</i> malaria: an open-label randomised trial. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 673-681.	9.1	168
104	Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of <i>Plasmodium vivax</i> malaria on the Thai-Myanmar border. <i>Malaria Journal</i> , 2010, 9, 308.	2.3	69
105	Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. <i>Malaria Journal</i> , 2010, 9, 105.	2.3	52
106	<i>Plasmodium falciparum</i> <i>pfmdr1</i> Amplification, Mefloquine Resistance, and Parasite Fitness. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1509-1515.	3.2	88
107	Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. <i>New England Journal of Medicine</i> , 2009, 361, 455-467.	27.0	2,873
108	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. <i>PLoS ONE</i> , 2009, 4, e4551.	2.5	212

#	ARTICLE	IF	CITATIONS
109	<i>Plasmodium vivax</i> resistance to chloroquine in Dawei, southern Myanmar. <i>Tropical Medicine and International Health</i> , 2008, 13, 91-98.	2.3	73
110	Gene Amplification of the Multidrug Resistance 1 Gene of <i>Plasmodium vivax</i> Isolates from Thailand, Laos, and Myanmar. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2657-2659.	3.2	74
111	Effects of Different Antimalarial Drugs on Gametocyte Carriage in <i>P. Vivax</i> Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 378-384.	1.4	46
112	Effects of different antimalarial drugs on gametocyte carriage in <i>P. vivax</i> malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2008, 79, 378-84.	1.4	29
113	Relapses of <i>Plasmodium vivax</i> Infection Usually Result from Activation of Heterologous Hypnozoites. <i>Journal of Infectious Diseases</i> , 2007, 195, 927-933.	4.0	266
114	Genetic Analysis of the Dihydrofolate Reductase-Thymidylate Synthase Gene from Geographically Diverse Isolates of <i>Plasmodium malariae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 3523-3530.	3.2	24
115	Contrasting genetic structure in <i>Plasmodium vivax</i> populations from Asia and South America. <i>International Journal for Parasitology</i> , 2007, 37, 1013-1022.	3.1	140
116	Genetic diversity of <i>Plasmodium vivax</i> in Kolkata, India. <i>Malaria Journal</i> , 2006, 5, 71.	2.3	74
117	Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2005, 99, 142-149.	1.8	26
118	Limited Polymorphism in the Dihydropteroate Synthetase Gene (dhps) of <i>Plasmodium vivax</i> Isolates from Thailand. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4393-4395.	3.2	63
119	Practical PCR genotyping protocols for <i>Plasmodium vivax</i> using Pvc3 and Pvmsp1. <i>Malaria Journal</i> , 2005, 4, 20.	2.3	128
120	The genetic diversity of <i>Plasmodium vivax</i> populations. <i>Trends in Parasitology</i> , 2003, 19, 220-226.	3.3	115
121	Novel Point Mutations in the Dihydrofolate Reductase Gene of <i>Plasmodium vivax</i> : Evidence for Sequential Selection by Drug Pressure. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1514-1521.	3.2	124
122	Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in <i>Plasmodium vivax</i> . <i>Molecular and Biochemical Parasitology</i> , 2002, 119, 63-73.	1.1	70
123	<i>Plasmodium vivax</i> : Polymerase Chain Reaction Amplification Artifacts Limit the Suitability of pvgam1 as a Genetic Marker. <i>Experimental Parasitology</i> , 2001, 99, 175-179.	1.2	13
124	Association of Genetic Mutations in <i>Plasmodium vivax</i> dhfr with Resistance to Sulfadoxine-Pyrimethamine: Geographical and Clinical Correlates. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3122-3127.	3.2	131